N

Noile-Immune Biotech Inc
TSE:4893

Watchlist Manager
Noile-Immune Biotech Inc
TSE:4893
Watchlist
Price: 156 JPY -2.5% Market Closed
Market Cap: 6.8B JPY
Have any thoughts about
Noile-Immune Biotech Inc?
Write Note

Noile-Immune Biotech Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Noile-Immune Biotech Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
N
Noile-Immune Biotech Inc
TSE:4893
Cash from Operating Activities
-ÂĄ873.1m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Cash from Operating Activities
ÂĄ48.9m
CAGR 3-Years
-62%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
PeptiDream Inc
TSE:4587
Cash from Operating Activities
ÂĄ27.1B
CAGR 3-Years
61%
CAGR 5-Years
48%
CAGR 10-Years
67%
Takara Bio Inc
TSE:4974
Cash from Operating Activities
ÂĄ5.7B
CAGR 3-Years
-32%
CAGR 5-Years
-3%
CAGR 10-Years
9%
Pharma Foods International Co Ltd
TSE:2929
Cash from Operating Activities
ÂĄ5.5B
CAGR 3-Years
-3%
CAGR 5-Years
127%
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Cash from Operating Activities
-ÂĄ451.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Noile-Immune Biotech Inc
Glance View

Market Cap
6.8B JPY
Industry
Biotechnology

Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.

Intrinsic Value
92.15 JPY
Overvaluation 41%
Intrinsic Value
Price
N

See Also

What is Noile-Immune Biotech Inc's Cash from Operating Activities?
Cash from Operating Activities
-873.1m JPY

Based on the financial report for Dec 31, 2023, Noile-Immune Biotech Inc's Cash from Operating Activities amounts to -873.1m JPY.

What is Noile-Immune Biotech Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-43%

Over the last year, the Cash from Operating Activities growth was -715%. The average annual Cash from Operating Activities growth rates for Noile-Immune Biotech Inc have been -43% over the past three years .

Back to Top